GlobalData epidemiologists project TB cases across the 16 major markets to reach 4.5 million by 2033. It has been several years since a new tuberculosis (TB) drug advanced into Phase III trials, but momentum in the field is now picking up, with a vaccine and two novel treatments progressing through late-stage studies.
The current standard of care (SoC) vaccine for TB is the Bacillus Calmette-Guérin (BCG) vaccine. It remains the only licensed TB vaccine and is one of the most widely administered globally. However, its protection is largely limited to infants and young children, and there is still no approved vaccine that effectively prevents pulmonary TB in adolescents and adults.
Regarding treatment, currently regimens include a six-month regimen, which consists of two months of isoniazid, rifampin, pyrazinamide, ethambutol and four months of isoniazid and rifampin (HR). For multi-drug resistant (MDR) TB, recommended treatment is a six-month regimen of bedaquiline, pretomanid, linezolid, and moxifloxacin, alongside other longer or alternative regimens depending on resistance profiles and clinical factors.